Roche Stock News

SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the AI company building a computer-aided design suite for protein-based therapeutics, announced a collaboration with Roche.

The new cobas ® eplex RP3 panel detects up to 19 viruses and bacteria, with newly added Bordetella pertussis and improved inclusivity of influenza A and SARS-CoV-2 strains, from a single sample to inform timely patient management. Laboratories can optimize resources with up to five flexible panel configurations tailored to local disease prevalence and patient needs, enabled by cobas® eplex syst...

Basel, 27 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has received the CE Mark for its cobas smart e immunoanalyser, a compact, standalone platform engineered to deliver reliable testing with a planned menu of over 100 high-medical-value assays.1,2 As the latest offering in Roche's industry-leading cobas immunoassay systems portfolio, the platform bridges critical ...

The Swiss drugmaker expects a pill it is developing to become the new standard treatment for an advanced form of lung cancer, and the company's first shot at an emerging field within the oncology market.

Swiss drugmaker Roche said on Sunday its experimental lung cancer drug divarasib reduced ​the risk of death by 44% compared ‌with existing treatments in a phase III study.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Divarasib demonstrated best-in-class efficacy in Phase III trial, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer.

Basel, 25 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today pivotal results from the phase III Krascendo 1 study, which demonstrated the superior efficacy of investigational divarasib, a next-generation KRAS G12C inhibitor, compared with current standard of care KRAS G12C inhibitors in people with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC).

Basel, 23 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today late-breaking oral presentation data from the ongoing phase III IMAgINATION study in adults with primary IgA nephropathy (IgAN) receiving optimised standard of care, demonstrating that investigational sefaxersen achieved a statistically significant and clinically meaningful 43.1% reduction in proteinuria (95% confidence...